| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() AUA MEETING: Patients Prefer Self-Injections To Urethral Suppositories For Impotence NEW YORK, NY -- June 2, 1998 -- Researchers at The New York Hospital-Cornell Medical Center found that 64 percent of patients (14 out of 22) who participated in a clinical/home research trial preferred self-injections over urethral suppositories for treatment of impotence. Their findings were presented at today's meeting of the American Urological Association in San Diego. On an overall satisfaction scale ranging from zero (lowest) to five (highest), patients rated self-injections at 3.2 compared to 1.5 with urethral suppositories. Although each treatment is administered differently, they both use the same active drug -- alprostadil. "Our study is the first to follow patients in clinical and home settings using both of these therapies," said Dr. J. Francois Eid, one of the lead investigators and director of the Sexual Function Unit at New York-Cornell. "We found that both patients and their partners reported significantly higher levels of satisfaction with the self-injections." The six-month randomised study followed 22 patients who were tested for quality of erection, patient and partner satisfaction. Overall quality of erection ratings in the clinical setting favoured self-injections (3.1) over suppositories (2.3). Overall quality of erection ratings in the home setting also favoured self-injections (2.8) over suppositories (1.5). Patient satisfaction ratings measured self-injections at a mean score of 3.2 compared to suppositories at a mean score of 1.5. Partner satisfaction measured self-injections at a mean score of 3.0 compared to suppositories at a mean score of 1.8. "Thanks to new options, more men are seeking treatment for impotence," Dr. Eid said. "It is important that we continue to evaluate the available medications for effectiveness, safety and overall patient satisfaction."
|